Ligand Pharmaceuticals Incorporated (LGND) Balance Sheet
A balance sheet shows what a company owns and owes, and shareholders' equity, at a single point in time.
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide.
Total Assets Chart for Ligand Pharmaceuticals Incorporated
Ligand Pharmaceuticals Incorporated (LGND) total assets for FY2025 were USD 1.6B, a 65.7% change from FY2024. Ligand Pharmaceuticals Incorporated's total assets grew from USD 46.7M in 1994 to USD 1.6B in 2025 (3241.8% over 31 years). Total assets compound annual growth rate: 5-year CAGR of 2.8%, 10-year CAGR of 11.3%, 20-year CAGR of 8.3%.
Total Assets (US Dollars)
R&D as % of Revenue
Compare with
Key Stats
- Market Cap
- $6.05B
- Implied Share Price
- $303.53
- Enterprise Value
- $5.72B
- Revenue (TTM)
- $290.54M
- EBITDA
- $133.01M
- Profit Margin
- 67.88%
- Trailing P/E
- 32.46
- Forward P/E
- 24.81
- Price/Book (MRQ)
- 6.16
- Price/Sales (TTM)
- 20.83
- EV/EBITDA
- 20.64
- EV/Revenue
- 19.68
- Dividend Yield
- —
- Book Value
- $48.57
- Free Cash Flow (FY2025)
- $48.91M
- Free Cash Flow Yield
- 0.81%
Snapshot as of 24th October 2026 — not point-in-time controlled, may lag the live market by a few days.